financetom
Business
financetom
/
Business
/
EV maker Nikola exploring options including potential sale, Bloomberg News reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EV maker Nikola exploring options including potential sale, Bloomberg News reports
Jan 23, 2025 1:24 PM

Jan 23 (Reuters) - EV maker Nikola ( NKLA ) is exploring

options including selling parts of its business or the entire

company as it struggles with a cash crunch, Bloomberg News

reported on Thursday.

(Reporting by Arsheeya Bajwa in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration
May 6, 2024
04:37 AM EDT, 05/06/2024 (MT Newswires) -- Lantern Pharma ( LTRN ) and Oregon Therapeutics are partnering to develop drug candidate XCE853 as a cancer treatment, the companies said Monday. Under the terms of the agreement, Lantern Pharma ( LTRN ) will receive equal intellectual property ownership and drug development rights in any newly discovered research findings or treatment strategies...
French carmakers target fourfold jump in EV sales by 2027
French carmakers target fourfold jump in EV sales by 2027
May 6, 2024
PARIS (Reuters) - France's car industry will aim to ramp up electric car sales fourfold by 2027 under a strategy agreement to be signed with the government on Monday, just as the president of China embarks on a state visit in the country. French President Emmanuel Macron has set a goal for the nation's carmakers to produce two million electric or...
Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints
Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints
May 6, 2024
04:56 AM EDT, 05/06/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Monday that data from a phase 2 trial of its drug candidate setanaxib in combination with pembrolizumab in patients with head and neck cancer met its secondary endpoints, including progress-free survival and overall survival. The randomized, placebo-controlled, double-blind study of 55 patients with squamous cell carcinoma of...
Japanese Yen Underperforms as Australian Dollar Leads G10 FX Higher
Japanese Yen Underperforms as Australian Dollar Leads G10 FX Higher
May 6, 2024
04:36 AM EDT, 05/06/2024 (MT Newswires) -- The Japanese yen fell against all major currencies in early European trade on Monday while the Australian dollar outperformed following a robust performance from risk assets in the Asian trading session. USD/JPY was the biggest mover among major currency pairs, rising 0.58% in Asia to be quoted around 153.72 following the European open....
Copyright 2023-2026 - www.financetom.com All Rights Reserved